Voriconazole
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Candidiasis
Conditions
Candidiasis, Cryptococcosis, Aspergillosis
Trial Timeline
Apr 1, 2003 → May 1, 2004
NCT ID
NCT00647907About Voriconazole
Voriconazole is a approved stage product being developed by Pfizer for Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00647907. Target conditions include Candidiasis, Cryptococcosis, Aspergillosis.
What happened to similar drugs?
4 of 20 similar drugs in Candidiasis were approved
Approved (4) Terminated (4) Active (13)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01092832 | Phase 3 | Terminated |
| NCT00836875 | Phase 3 | Terminated |
| NCT00855101 | Phase 1 | Completed |
| NCT00721578 | Pre-clinical | Completed |
| NCT00556998 | Phase 2 | Completed |
| NCT00455364 | Approved | Terminated |
| NCT00300677 | Approved | Completed |
| NCT01660334 | Pre-clinical | Completed |
| NCT01151085 | Pre-clinical | Completed |
| NCT00288197 | Approved | Completed |
| NCT00159822 | Phase 2/3 | Completed |
| NCT00136968 | Phase 1 | Completed |
| NCT00143312 | Approved | Completed |
| NCT00174473 | Phase 1/2 | Completed |
| NCT00647907 | Approved | Completed |
Competing Products
20 competing products in Candidiasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Phase 1 | 29 |
| Isavuconazole + Caspofungin + Voriconazole | Astellas Pharma | Phase 3 | 40 |
| Micafungin + fluconazole | Astellas Pharma | Phase 3 | 40 |
| Micafungin (Mycamine) | Astellas Pharma | Phase 1 | 29 |
| Fluconazole + Micafungin | Astellas Pharma | Approved | 35 |
| Micafungin + Caspofungin | Astellas Pharma | Phase 3 | 40 |
| Micafungin + Fluconazole | Astellas Pharma | Phase 3 | 40 |
| Micafungin | Astellas Pharma | Phase 2 | 35 |
| micafungin + caspofungin | Astellas Pharma | Phase 3 | 40 |
| micafungin + amphotericin B deoxycholate | Astellas Pharma | Phase 3 | 32 |
| FK463 | Astellas Pharma | Phase 2 | 35 |
| Micafungin + Liposomal Amphotericin B | Astellas Pharma | Phase 3 | 40 |
| SHR8008 + Fluconazole | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| SHR8008 capsule + Fluconazole capsule | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| L-743,872 | Merck | Pre-clinical | 26 |
| Caspofungin | Merck | Phase 2 | 35 |
| L-743,872 | Merck | Phase 2 | 27 |
| Caspofungin + Amphotericin B Deoxycholate | Merck | Phase 2 | 27 |
| Caspofungin acetate + Placebo | Merck | Phase 2 | 27 |
| Caspofungin + Normal Saline | Merck | Approved | 43 |